Atropine for sedation emergencies is the go-to when moderate sedation produces symptomatic bradycardia — a heart rate low enough to bring blood pressure down with it. Atropine increases heart rate by blocking vagal stimulation.
Dosage:
Initial dose: 0.4-1 mg IV (adult)
Additional doses: titrate to effect within 0.4-1 mg range · Pediatric (>5 kg): 0.01-0.2 mg/kg, minimum dose 0.1 mg
Onset of action: 45-60 seconds
Peak effect: 2 minutes
Duration of effect: 1-2 hours
Reversal Agent:
None
Atropine in Moderate Sedation
During moderate sedation, atropine is reserved for symptomatic bradycardia — a heart rate low enough to cause hypotension, dizziness, or reduced perfusion — rather than given prophylactically. Continuous ECG and blood pressure monitoring should already be running before the dose is given, and both should be reassessed within a few minutes to confirm the heart rate and pressure have responded before considering an additional dose. Because atropine has no pharmacologic reversal agent, its effect runs its course; a patient who becomes tachycardic after dosing is managed by monitoring and supportive care, not by a reversal drug. As with any medication given during moderate sedation, administration follows the facility’s sedation policy and the provider’s scope of practice.
Educational reference for sedation providers, relocated from the previous version of this site — not a substitute for the current package insert, your facility protocols, or clinical judgment. Verify all doses against current references before clinical use.